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Abstract
Objective—Neuropsychiatric symptoms affect 37% of US adults. These symptoms are often 
refractory to standard therapies, and patients may consequently opt for complementary and 
alternative medicine therapies (CAM). We sought to determine the demand for CAM by those 
with neuropsychiatric symptoms compared to those without neuropsychiatric symptoms as 
measured by out-of-pocket expenditure.
Method—We compared CAM expenditure between US adults with and without neuropsychiatric 
symptoms (n = 23,393) using the 2007 National Health Interview Survey. Symptoms included 
depression, anxiety, insomnia, attention deficits, headaches, excessive sleepiness, and memory 
loss. CAM was defined per guidelines from the National Institutes of Health as mind-body 
therapies, biological therapies, manipulation therapies, or alternative medical systems. 
Expenditure on CAM by those without neuropsychiatric symptoms was compared to those with 
neuropsychiatric symptoms.
Results—Of the adults surveyed, 37% had ≥ 1 neuropsychiatric symptom and spent $ 14.8 
billion out-of-pocket on CAM. Those with ≥ 1 neuropsychiatric symptom were more likely than 
those without neuropsychiatric symptoms to spend on CAM (27.4% vs 20.3%, P < .001). 
Likelihood to spend on CAM increased with number of symptoms (27.2% with ≥ 3 symptoms, P 
< .001). After adjustment was made for confounders using logistic regression, those with ≥ 1 
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neuropsychiatric symptom remained more likely to spend on CAM (odds ratio [OR] = 1.34; 95% 
Cl, 1.22–1.48), and the likelihood increased to 1.55 (95% Cl, 1.34–1.79) for ≥ 3 symptoms. 
Anxiety (OR = 1.40 [95% Cl, 1.22–1.60]) and excessive sleepiness (OR=1.36 [95% Cl, 1.21–
1.54]) were the most closely associated with CAM expenditure.
Conclusions—Those with ≥ 1 neuropsychiatric symptom had disproportionately higher demand 
for CAM than those without symptoms. Research regarding safety, efficacy, and cost-
effectiveness of CAM is limited; therefore, future research should evaluate these issues given the 
tremendous demand for these treatments.
Neuropsychiatric symptoms affect more than 1 in 3 adults in the United States.1,2 This group 
of symptoms, including insomnia, anxiety, attention deficits, memory loss, regular 
headaches, excessive sleepiness, and depression, often occurs as a constellation rather than 
as individual symptoms.1,2 While these symptoms can be present in otherwise healthy 
individuals, the constellation is frequently present in those suffering from neuropsychiatric 
conditions including posttraumatic stress disorder (PTSD), traumatic brain injury (TBI), 
mild cognitive impairment (MCI), dementia, and fibromyalgia.3–5 Individual 
neuropsychiatric symptoms have also been shown to be independent risk factors for other 
chronic medical conditions such as insomnia and obesity, metabolic syndrome, 
cardiovascular disease, and stroke.6–9 Furthermore, they are associated with risky behaviors 
(eg, substance abuse, drunk driving, dangerous sexual behaviors), and decreased work 
productivity.10 Standard treatments for neuropsychiatric symptoms vary according to the 
associated disease entities, but these symptoms as a whole are often notoriously difficult to 
treat. Additionally, despite conventional options, including pharmacologic intervention and 
mental health visits, patients continue to seek other options for relief of these symptoms.1
Complementary and alternative medicine (CAM) encompasses a wide range of therapies 
including acupuncture, meditation, yoga, biofeedback, massage therapy, and herbal 
medications.11 Prior studies have estimated that Americans spend $34 billion out-of-pocket 
annually for CAM treatments.12 Several of these CAM treatments, with varying degrees of 
underlying evidence, may offer additional options to those suffering from neuropsychiatric 
symptoms.
In our prior work,1 we reported higher prevalence of CAM use among adults with 
neuropsychiatric symptoms compared to those without neuropsychiatric symptoms (44% vs 
30%, P < .001). The 3 modalities most likely to be used include herbal medications, deep-
breathing exercises, and meditation. Mind-body therapies were the most popular 
subcategory.1,2 In addition, there was a positive association between the number of 
neuropsychiatric symptoms and CAM use, with those having more symptoms more likely to 
use CAM, particularly mind-body medicine.1,2 Preliminary studies13–15 with these mind-
body interventions have suggested improvements in sleep dysfunction, anxiety, and 
attention deficits. For example, mindfulness-based stress reduction, an 8-week group yoga 
and meditation course, has shown improvement in anxiety, depression, insomnia, and 
quality of life.13–17 Studies18 with acupuncture have suggested potential benefit for 
cognition and sleep quality. Several studies19,20 suggest the beneficial effects of meditation 
for attention and memory processes. Some studies19,21–24 of meditation and yoga have also 
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suggested beneficial changes both neurostructurally and neurophysiologically, with changes 
in cortical gray matter, as well as changes with γ-aminobutyric acid (GABA) and glutamate 
production providing a potential neural mechanistic pathway for the improvements 
observed. However, several studies25,26 investigating nutriceuticals or herbal therapies for 
individual neuropsyehiatric symptoms, such as St. John’s wort for anxiety and depression 
and ginkgo for memory have had equivocal results at best. Also, while many types of CAM 
are generally regarded as relatively safe, questions of safety and herb-drug interactions exist 
with supplements.27–29
Irrespective of the evidence base, with significant CAM use by the general population, 
significant out-of-pocket costs are assumed. However, to our knowledge, no studies have 
been published evaluating CAM expenditure in patients with neuropsyehiatric symptoms. 
Out-of-pocket expenditure represents a significant interest by the consumer, indicating a 
willingness to invest a finite resource beyond regular expenditures on health insurance and 
standard treatments. In order to inform future clinical and cost-effectiveness research, 
facilitate discussion among various stakeholders, and inform eventual public policy 
regarding CAM treatments, it is imperative to understand consumer use and expenditure of 
CAM, particularly in a population in which neuropsyehiatric symptoms are pervasive and 
span multiple important medical conditions. Thus, understanding costs associated with 
CAM therapies is an important indicator of consumer interest and demand.
In this context, utilizing a nationally representative survey, we aimed to further analyze 
patterns of consumer cost and expenditure for CAM specifically in those with 
neuropsyehiatric symptoms.
METHOD
Data Source
We analyzed data from the 2007 National Health Interview Survey (NHIS) Adult Core and 
Alternative Medicine Supplement. The NHIS is conducted by the Centers for Disease 
Control and Prevention and uses a complex sampling design to select a nationally 
representative sample of households for face-to-face interviews. One adult, aged 18 years or 
older, was randomly selected from each household to answer the adult questionnaire.30 In 
2007, the NHIS used a supplement questionnaire, sponsored by the National Institutes of 
Health, to obtain information regarding national out-of-pocket expenditures for CAM 
therapy use.30 Details of the survey description including specific questions and response 
options are publicly available on the NHIS website.30,31 The final adult survey included 
23,393 respondents, with an overall response rate of 67.8%.30 Of these respondents, 8,696 
individuals had neuropsyehiatric symptoms; this study will focus on comparing these 
individuals to those without neuropsyehiatric symptoms.
Data Collection
Neuropsychiatric symptoms—Of the information surveyed, the most common 
neuropsyehiatric symptoms include memory loss, insomnia, regular headaches, anxiety, 
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excessive sleepiness, attention deficits, and depression.31 Presence of symptoms was based 
on self-report.
Outcomes of interest—Our primary outcome was the total expenditure for CAM by 
those with ≥ 1 neuropsyehiatric symptom compared to those without any symptoms in the 
prior 12 months. We were also interested in the correlation between increasing number of 
neuropsyehiatric symptoms and expenditure on CAM.
Complementary and alternative medicine therapies were grouped into 4 categories: 
alternative medical systems (Ayurveda, acupuncture, homeopathy, naturopathy, and 
traditional healers), manipulation/bodywork therapies (massage, chiropractic care, 
Feldenkrais, Alexander technique, pilates, Trager Psychophysical Integration), biologically 
based therapies (herbal therapies, chelation therapy, special diets), and mind-body therapies 
(biofeedback, energy healing, hypnosis, tai chi, yoga, qi gong, meditation, guided imagery, 
progressive relaxation, deep breathing exercises). Each of these therapies is additionally 
classified in NHIS as a practitioner-based or self-care therapy. To maintain consistency with 
previous studies, we included the therapies as listed above and excluded prayer, vitamin use, 
support group meetings, and stress-management classes.
Correlates of CAM use—Data were collected on sociodemographic and clinical 
characteristics such as gender, age, race/ethnicity, region of residence, birthplace, 
educational attainment, and marital status. Potential indicators of illness burden included 
perceived health status, presence of functional limitations, self-reported history of medical 
conditions, insurance status, imputed family income provided by the NHIS, smoking status, 
physical activity level, alcohol intake, and presence of chronic medical and neurologic 
diagnoses such as cardiovascular disease, stroke, and chronic pain syndromes. Covariates 
were included if either previously reported as significant or considered important and 
relevant to our topic.32–36
Calculation of expenditures—To maintain consistency and allow for a fair comparison 
with previous studies, we used the published methods described by Barnes et al12 for the 
calculation of expenditures. In brief, we used recodes provided by the NHIS for the number 
of times the respondent saw a CAM practitioner, the amount paid out-of-pocket for each 
CAM practitioner visit or therapy used, the number of times these visits or purchases 
occurred, and the amount paid out-of-pocket for a self-care therapy. Details of these 
methods are available in the study conducted by Barnes et al.12 Persons with unknown CAM 
information were excluded from the analysis.
On the basis of prior testing results of the Complementary and Alternative Medicine 
Supplement of the 2007 NHIS,12 few respondents reported purchasing supplements as often 
as daily. Responses indicating purchases more than 365 times per year were therefore 
excluded from the analysis as presumed errors.
Statistical Analyses
We used bivariable analyses to compare out-of-pocket expenditure on CAM between adults 
with and without neurologic and psychiatric symptoms. We also examined the correlation 
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between increasing number of neuropsychiatric symptoms and prevalence and category of 
CAM use with χ2 analysis.
We fit multiple multivariable logistic regression models to determine (1) whether 
differences in likelihood of out-of-pocket expenditure on CAM persisted between adults 
with and without common neuropsychiatric symptoms after adjusting for sociodemographic 
and clinical factors, as described above; (2) whether an increase in the number of these 
symptoms was associated with an increased likelihood of out-of-pocket expenditure on 
CAM after adjusting for covariates; and (3) which specific symptoms were more closely 
associated with a higher likelihood of higher out-of-pocket expenditure on CAM.
All models used the same covariates as described in detail above. To ensure a robust 
analysis, we did not eliminate any of the covariates after initial inclusion.
Estimates excluded missing data; no individual variable had more than 5.8% missing data. 
Regression models included respondents with complete data on all covariates.
We used SAS (version 9.3; Research Triangle Park, North Carolina) to account for the 
complex sample design and used NHIS parameters so that the results reflect national 
estimates.30 Imputed incomes were provided by the NHIS. The study was approved for 
exemption by the Spaulding Rehabilitation Hospital Institutional Review Board.
RESULTS
Sample Characteristics
General characteristics of the sample have been previously reported.1,2 In brief, 8,696 adults 
reported experiencing at least 1 neuropsychiatric symptom, representing 37% of the US 
adult population (estimated 81.6 million adults nationwide).1,2 For individual 
neuropsychiatric symptoms, 18% reported insomnia (estimated 40 million adults), 15% 
reported regular headaches (estimated 34 million adults), 11% reported anxiety (estimated 
24 million adults), 11% reported depression (estimated 24 million adults), 10% reported 
excessive sleepiness (estimated 23 million adults), 6% reported memory loss (estimated 12 
million adults), and 3% reported attention deficit (estimated 6 million adults).1,2 Of the total 
population surveyed, 63% (n= 14,697) reported no neuropsychiatric symptoms, 18.2% (n = 
4,261) reported 1 symptom, 8.5% (n= 1,992) reported 2 symptoms, and 10.4% (n = 2,443) 
reported ≥ 3 symptoms. Those reporting ≥ 1 neuropsychiatric symptoms differed in many 
ways from those without such symptoms (Table 1).1,2 In the descriptive analyses, of those 
adults with ≥1 neuropsychiatric symptom, females, middle age brackets, non-Hispanic white 
respondents, lower income brackets, US born, those needing assistance with ADLs, alcohol 
consumers, and those with chronic medical conditions were more likely to have a 
neuropsychiatric symptom.
CAM Expenditures
Of the adults surveyed, 37% had ≥ 1 neuropsychiatric symptom and spent $14.8 billion out 
of pocket on CAM. Overall, 23.4% of US adults had ≥ 1 expenditure on a CAM therapy in 
the prior 12 months. Of those with ≥ 1 neuropsychiatric symptom, 28.5% made an 
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expenditure in the prior 12 months compared to 14.8% of those without any symptoms (P 
< .001), with the percentage of the population making an expenditure increasing with the 
number of symptoms to over 27.2% in those with ≥ 3 neuropsychiatric symptoms (Figure 1; 
P < .001). Expenditure by those with ≥1 neuropsychiatric symptom (36.6% of the 
population) represents 44.7% of the total out-of-pocket expenditure of the overall 
population. By CAM category, those with and without symptoms spent the most on 
biological therapies, followed by manipulation/body work therapies, mind-body therapies, 
and alternative medical systems (Figure 2). However, per capita expenditure is 
disproportionately higher in those with neuropsychiatric symptoms for all categories.
Even after we adjusted for covariates, those with ≥ 1 neuropsychiatric symptom were more 
likely to have an expenditure on CAM (OR=1.34 [95% CI, 1.22-1.48]). This likelihood 
increased with an increasing number of symptoms (1 symptom: OR=1.24 [95% CI, 
1.10-1.40]; 2 symptoms: OR=1.45 [95% CI, 1.24-1.70]; ≥3 symptoms: OR=1.55 [95% CI, 
1.34-1.79]). Female gender, higher level of education, higher income, those needing help 
with ADLs, those that perceived their health as good or better, those with higher levels of 
physical activity, and history of chronic medical conditions were all associated with higher 
likelihood of CAM expenditure (Table 2). In evaluating specific symptoms, anxiety, 
excessive sleepiness, depression, and insomnia were associated with an increased likelihood 
of CAM expenditure, with memory loss showing a trend toward significance (Figure 3).
DISCUSSION
We found that US adults with ≥1 neuropsychiatric symptom spent disproportionately more 
on CAM compared to adults without neuropsychiatric symptoms. Furthermore, more 
neuropsychiatric symptoms correlated with higher likelihood of CAM expenditure. 
Respondents with anxiety, depression, and sleep dysfunction had the highest likelihood of 
CAM expenditure.
Given the tremendous prevalence of neuropsychiatric symptoms and the difficulties in 
treating these symptoms with standard treatments, identifying patterns of consumer use and 
expenditure of alternative treatments is important for this population. To our knowledge, this 
is the first evaluation of the expenditure on CAM by this population of patients on a national 
scale. This population was studied because nearly 37% of the general population reports at 
least 1 neuropsychiatric symptom as well as the relevance of these neuropsychiatric 
symptoms to many conditions, including PTSD, TBI, MCI, dementia, and fibromyalgia.1,3–5 
Our previous studies have shown that there is a prevalence of CAM usage by those with 
neuropsychiatric symptoms. This study expands on previous work by investigating actual 
out-of-pocket expenditure in addition to prevalence.
Consistent with previous studies estimating prevalence, we found that having at least 1 
neuropsychiatric symptom is significantly associated with CAM expenditure. Those with 
neuropsychiatric symptoms had disproportionately higher out-of-pocket expenditure on 
CAM than those without these symptoms. Interestingly, our prior study1,2 found the 
prevalence of CAM use to be 44% by those with neuropsychiatric symptoms, while the 
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percentage of respondents with symptoms having a CAM expenditure in this analysis was 
relatively less, 28.5%.
One potential reason for the difference in prevalence compared to expenditure is that many 
types of CAM may not always require a purchase including lifestyle or self-care 
interventions, (eg, yoga, meditation, and tai chi). Mind-body therapies were, in fact, the 
most frequently used modality. However, they were much lower on the list in terms of 
expenditure. Furthermore, other modalities such as herbal medications and manipulation 
therapies (eg, massage) require repeated expenditure for use, whereas mind-body therapies, 
once learned, can potentially be adopted without further expense.
The high overall prevalence and expenditure on CAM argues that these treatments are 
increasingly becoming mainstream. For example, in 2007, total out-of-pocket expenditure 
on CAM was $34.2 billion.12 This number starts to approach other out-of-pocket health care 
expenses such as $49.6 billion for conventional physician visits and $52.5 billion for 
prescription medications in the same year.37 In fact, the $34.2 billion spent on CAM 
represents 11.2% of total out-of-pocket health care expenditures for 2007.37 As such, this 
consumer demand places an imperative on research evaluating the safety, efficacy, and cost 
of these therapies, including comparative cost-effectiveness analysis between CAM and 
conventional treatments.
CAM treatments, particularly those related to lifestyle such as mind-body therapies (eg, 
yoga, meditation, tai chi), may have relatively lower cost, have fewer side effects, and allow 
for active patient participation and personal responsibility. There is also some evidence to 
suggest benefit of mind-body therapies for a range of neuropsychiatric and chronic medical 
conditions as previously discussed.
Some have suggested that the use of CAM may affect health care expenditures in a positive 
way, although this area is still understudied.38 Limited or no data exist on how the use of 
CAM impacts conventional provider visits, prescription medication usage, procedures, or 
even health insurance coverage. For example, one may postulate that CAM can serve as 
adjuvant treatment helping to lower the cost and demand of more expensive treatments (eg, 
lifestyle changes compared to gastric bypass surgery) or decrease the dose of medications 
with high side effect profiles (eg, lessen the dose of pain medications for patients with 
chronic pain). At the same time, it is possible that use of herbal medications in conjunction 
with standard medications may cause more interaction risks and thus increase emergency 
room visits. Further study is thus needed to make these determinations.
We also identified clear differences between adults that do spend on CAM versus those that 
do not in terms of race and gender, among other factors. It is unclear whether these 
differences represent disparities in care or different preferences based on culture and 
background, particularly given different perceptions of disease and healing care in various 
cultures.
We acknowledge that the NHIS survey we utilized has some inherent limitations. First, 
recall bias by the respondents may have been present. Second, the total costs per person for 
nonvitamin, nonmineral natural products and homeopathy were estimates (calculated by 
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multiplying the amount spent at the most recent purchase by the number of purchases per 
year). As the most recent purchase may not have been typical of the respondent's usual 
purchase of CAM products, the estimates may contain errors. Third, the sample size in the 
subgroups does not allow for evaluation of whether CAM therapies were used specifically 
for the neuropsychiatric symptoms. Finally, the conditions were self-reported. These 
limitations are common to survey-based studies and are unavoidable for this analysis, as no 
claims data on CAM exists.
Despite these limitations, this nationally representative survey provides tremendous insight 
into the consumer demand for a comprehensive and detailed list of CAM therapies. 
Additionally, to our knowledge, this is the first evaluation of CAM expenditure by this 
important population of patients on a national scale.
CONCLUSION
US adults with neuropsychiatric symptoms comprised a significant percentage of total CAM 
expenditure in 2007. Increasing numbers of neuropsychiatric symptoms were associated 
with increased expenditure. Anxiety, depression, and sleep dysfunction were most 
associated with CAM expenditure. Given the demand for CAM therapies, this study 
highlights the importance of research evaluating the efficacy, safety, and cost-effectiveness 
of these treatments.
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Clinical Points
■ This study shows the high demand for complementary and alternative 
medicine therapies, particularly for biological or herbal products.
■ Since many people in this population may be using standard medications as 
well, it is important that the clinical provider discuss these therapies along 
with standard treatments, as interactions between herbal products and 
prescription medications are possible.
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Figure 1. 
Number of Neuropsychiatric Symptoms and Prevalence of Out-of-Pocket Expenditure on 
Complementary and Alternative Medicine
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Figure 2. 
Complementary and Alternative Medicine Expenditure Per Capita by Therapy Category
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Figure 3. 
The Likelihood of Out-of-Pocket Expenditure on Complementary and Alternative Medicine 
by Type of Neuropsychiatric Symptom: Multivariable Models
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Table 1
Sample Characteristicsa
Sociodemographic
Characteristic
Individuals With
Neuropsychiatric
Symptoms,
n (weighted %)
Individuals Without
Neuropsychiatric
Symptoms,
n (weighted %)
Total 8,696 14,692
Gender
   Male 3,271 (37.6) 7,102 (48.3)
   Female 5,425 (62.4) 7,590 (51.7)
Age, y
   18–24 856 (9.8) 1,638 (11.2)
   25–44 2,992 (34.4) 5,548 (37.8)
   45–64 2,973 (34.2) 4,801 (32.7)
   65–74 900 (10.4) 1,515 (10.3)
   ≥75 975 (11.2) 1,190 (8.1)
Race
   Hispanic 1,477 (17.0) 2,719 (18.5)
   Non-Hispanic white 5,393 (62.0) 8,656 (58.9)
   Non-Hispanic black 1,371 (15.8) 2,334 (15.9)
   Non-Hispanic Asian 352 (4.1) 882 (6.0)
   Non-Hispanic other 103 (1.2) 101 (0.7)
Education
   High school or less 4,336 (49.9) 6,407 (43.6)
   > High school 4,296 (49.4) 8,089 (55.1)
Imputed family incomeb
   0–$ 19,999 2,714 (31.2) 3,016 (20.5)
   $20,000–$34,999 1,843 (21.2) 2,667 (18.2)
   $35,000–$64,999 2,085 (24.0) 4,079 (27.8)
   ≥ $65,000 2,054 (23.6) 4,930 (33.6)
Region
   Northeast 1,389 (16.0) 2,531 (17.2)
   Midwest 1,918 (22.1) 3,302 (22.5)
   South 3,316 (38.1) 5,399 (36.8)
   West 2,073 (23.8) 3,460 (23.6)
Marital status
   Married/living with partner 4,059 (46.7) 7,936 (54.0)
   Widowed/divorced/separated 2,731 (31.4) 3,316 (22.6)
   Never married 1,881 (21.6) 3,334 (22.7)
US born 7,251 (83.4) 11,559 (78.7)
Foreign born 1,442 (16.6) 3,118 (21.2)
Insurance status
   Private 4,757 (54.7) 9,837 (67.0)
J Clin Psychiatry. Author manuscript; available in PMC 2016 January 27.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Purohit et al. Page 16
Sociodemographic
Characteristic
Individuals With
Neuropsychiatric
Symptoms,
n (weighted %)
Individuals Without
Neuropsychiatric
Symptoms,
n (weighted %)
   Public 2,346 (27.0) 2,326 (15.8)
   Uninsured 1,572 (18.1) 2,473 (16.8)
Needs help with activities of daily livingc 909 (10.5) 316 (2.2)
Does not need help with activities of daily livingc 7,786 (89.5) 14,374 (97.8)
Health characteristics
Body mass indexd
   Underweight 156 (1.8) 243 (1.7)
   Healthy weight 2,790 (32.1) 5,262 (35,8)
   Overweight 2,645 (30.4) 5,156 (35.1)
   Obese 2,675 (30.8) 3,189 (21.7)
Perceived healthe
   Excellent/very good/good 6,370 (73.3) 13,567 (92.3)
   Fair or poor 2,321 (26.7) 1,115 (7.6)
Physical activityf
   Inactive 3,887 (44.7) 5,640 (38.4)
   Insufficiently active 1,693 (19.5) 2,595 (17.7)
   Sufficiently active 2,876 (33.1) 6,001 (40.9)
Smoking
   Current/former 4,176 (48.0) 5,123 (34.9)
   Never 4,397 (50.6) 9,290 (63.2)
Alcohol
   Abstainer/former 3,477 (40.0) 5,755 (39.2)
   Current light/moderate/heavy 5,001 (57.5) 8,334 (56.7)
History of chronic medical conditionsg 6,543 (75.2) 6,024 (41.0)
Without history of chronic medical conditionsg 2,153 (24.8) 8,668 (59.0)
History of pain syndromesh 5,061 (58.2) 3,452 (23.5)
No history of pain syndromesh 3,635 (41.8) 11,235 (76.5)
a
Total number in sample is 23,393. Total number with symptoms is 8,696. Total number without symptoms is 14,692. Total number with missing 
data for symptoms is 5. The n’s in the table represent the unweighted number of persons with and without symptoms.
b
Incomes are imputed values provided by the National Health Interview Survey.
cActivities of daily living is based on the variables PLAADL (Because of a physical, mental, or emotional problem, [do you/does anyone in the 
family] need the help of other persons with personal care needs, such as eating, bathing, dressing, or getting around inside this home?) and 
PLAIADL (Because of a physical, mental, or emotional problem, do [you/ any of these family members] need the help of other persons in handling 
routine needs, such as everyday household chores, doing necessary business, shopping, or getting around for other purposes?).
d
Body mass index (kg/m2) is based on respondent reported height and weight. Categories of BMI are underweight (BMI < 18.5), healthy weight 
(18.5 < BMI < 25.0), overweight (25.0 < BMI < 30.0), and obese (BMI > 30.0).
e
Based on the question, “Would you say (person’s) health in general is excellent, very good, good, fair, or poor?”
f
Inactive is participating in no leisure-time aerobic activity that lasted at least 10 minutes. Insufficiently active is participating in aerobic activities 
for 10 minutes or more but less than 150 minutes per week. Sufficiently active is participating in moderate-intensity leisure-time physical activity 
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150 minutes or more per week, or in vigorous-intensity leisure-time physical activity 75 minutes or more per week, or an equivalent combination. 
Categories are mutually exclusive.
g
History of chronic medical conditions includes self-reported history of heart attack, coronary artery disease, angina in the past 12 months, poor 
circulation, history of urinary problems or weak/failing kidneys in the past 12 months, acid reflux/heartburn, bowel problems, ulcer, or liver 
condition in the past 12 months, history of emphysema or asthma, gout, lupus, fibromyalgia, rheumatoid arthritis, or arthritis.
h
History of chronic pain syndromes includes self-reported history of dental pain past 12 months, jaw/face pain past 3 months, neck pain past 3 
months, or low back pain in the past 3 months.
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Table 2
Likelihood of Out-of-Pocket Complementary and Alternative Medicine Expenditure: A Multivariable Model
Sododemographic Characteristic
Odds Ratio
(point estimate)
95%
Wald CI
≥ 1 Neuropsychiatric symptom 1.34 1.22–1.48
Without symptoms 1.00 (reference)
Adjustment factors
Gender
   Male 0.65 0.60–0.71
   Female 1.00 (reference)
Age, y
   18–24 0.61 0.51–0.74
   25–44 1.00 (reference)
   45–64 1.20 1.07–1.35
   65–74 1.40 1.20–1.64
   ≥75 0.92 0.75–1.14
Race
   Hispanic 0.66 0.55–0.79
   Non-Hispanic white 1.00 (reference)
   Non-Hispanic black 0.47 0.40–0.55
   Non-Hispanic Asian 0.92 0.74–1.13
   Non-Hispanic other 1.14 0.74–1.76
Education
   High school or less 0.57 0.52–0.64
   > High school 1.00 (reference)
Imputed family incomea
   0–$ 19,999 0.62 0.53–0.72
   $20,000–$34,999 0.71 0.62–0.82
   $35,000–$64,999 0.83 0.74–0.93
   ≥ $65,000 1.00 (reference)
Region
   Northeast 0.94 0.82–1.07
   Midwest 1.12 0.97–1.28
   South 1.00 (reference)
   West 1.36 1.20–1.56
Marital status
   Married/living with partner 1.00 (reference)
   Widowed/divorced/separated 1.05 0.93–1.18
   Never married 1.00 0.88–1.13
US born
   Yes 1.00 (reference)
   No 0.77 0.67–0.90
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Sododemographic Characteristic
Odds Ratio
(point estimate)
95%
Wald CI
Insurance status
   Private 1.00 (reference)
   Public 0.78 0.68–0.89
   Uninsured 0.94 0.81–1.09
Needs help with activities of daily livingb
   Yes 0.91 0.70–1.17
   No 1.00 (reference)
Health characteristics
Body mass index
   Underweight 0.66 0.44–0.98
   Healthy weight 1.00 (reference)
   Overweight 0.88 0.79–0.98
   Obese 0.91 0.82–1.01
Perceived health
   Excellent/very good/good 1.00 (reference)
   Fair or poor 0.91 0.82–1.02
Physical activity
   Inactive 0.44 0.39–0.49
   Insufficiently active 0.75 0.68–0.83
   Sufficiently active 1.00 (reference)
Smoking
   Current/former 1.03 0.93–1.13
   Never 1.00 (reference)
Alcohol
   Abstainer/former 0.70 0.64–0.77
   Current light/moderate/heavy 1.00 (reference)
History of chronic medical conditionsc
   Yes 1.00 (reference)
   No 0.71 0.64–0.79
History of pain syndromesd
   Yes 1.97 1.81–2.15
   No 1.00 (reference)
a
Incomes are imputed values provided by the National Health Interview Survey.
bActivities of daily living is based on the variables PLAADL (Because of a physical, mental, or emotional problem, [do you/does anyone in the 
family] need the help of other persons with personal care needs, such as eating, bathing, dressing, or getting around inside this home?) and 
PLAIADL (Because of a physical, mental, or emotional problem, do [you/ any of these family members] need the help of other persons in handling 
routine needs, such as everyday household chores, doing necessary business, shopping, or getting around for other purposes?).
c
History of chronic medical conditions includes self-reported history of heart attack, coronary artery disease, or angina in the past 12 months; poor 
circulation, history of urinary problems, or weak/failing kidneys in the past 12 months; acid reflux/heart burn, bowel problems, ulcer, or liver 
condition in the past 12 months; or history of emphysema or asthma, gout, lupus, fibromyalgia, rheumatoid arthritis, and/or arthritis.
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d
History of chronic pain syndromes includes self-reported history of dental pain past 12 months, jaw/face pain in past 3 months, neck pain in past 3 
months, and/or low back pain in the past 3 months.
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